Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Company in position for pre-sales license inspection, last step to issuance of a Sales License FSD Pharma Inc. (“FSD Pharma” or the “Company”) (OTC: FSDDF) (cse:HUGE)(fra:0K9) is pleased to announce that its wholly-owned subsidiary, FV […]
TORONTO—-FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of David Urban to the Company’s Board of Directors. Mr. Urban is an accomplished business and government […]
VANCOUVER, Washington, Sep 06, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
